Probability of non-invasive respiratory therapies failure in adults with COVID-19
新型冠状病毒感染患者无创呼吸支持失败的风险预测
Non-invasive respiratory therapies include high flow nasal cannula (HFNC) and non-invasive ventilation (NIV)
无创呼吸支持包括无创通气及经鼻高流量氧疗
*Input variables(输入变量)
Worst value on the first day of non-invasive respiratory therapies(无创呼吸支持第一天的最差值)
  1. 1、Age(年龄)
  2. 2、Glasgow coma score (GCS)(格拉斯哥昏迷评分)
  3. 3、Pulse oximetry (SPO₂)(经皮血氧饱和度)
  4. 4、Fraction of inspired oxygen (FiO₂) (吸入氧浓度)
  5. 5、Respiratory rate, breaths/min (呼吸频率, 次/分)
  6. 6、Number of Comorbidities (并存疾病个数)
Failure risk of Non-invasive respiratory therapies is (该患者无创呼吸支持失败的风险是)
  1. 1、Age(年龄)
  2. 2、Glasgow coma score (GCS)(格拉斯哥昏迷评分)
  3. 3、Pulse oximetry (SPO₂)(经皮血氧饱和度)
  4. 4、Fraction of inspired oxygen (FiO₂) (吸入氧浓度)
  5. 5、Respiratory rate, breaths/min (呼吸频率, 次/分)
  6. 6、Use of vasopressors(无创呼吸支持第一天是否应用血管活性药)
  7. 7、Days from symptom onset to hospital admission (从出现症状到入院的天数)
Failure risk of NIV is (该患者无创通气失败的风险是)
  1. 1、Age(年龄)
  2. 2、Glasgow coma score (GCS)(格拉斯哥昏迷评分)
  3. 3、Pulse oximetry (SPO₂)(经皮血氧饱和度)
  4. 4、Fraction of inspired oxygen (FiO₂) (吸入氧浓度)
  5. 5、Respiratory rate, breaths/min (呼吸频率, 次/分)
  6. 6、Use of vasopressors(无创呼吸支持第一天是否应用血管活性药)
  7. 7、Number of Comorbidities (并存疾病个数)
Failure risk of Non-invasive respiratory therapies is (该患者无创呼吸支持失败的风险是)
Submit (预测)
昨日访问量:1  总访问量:191